In the UK, from early 2024 to early 2025, approximately 1.6 million adults in England, Wales, and Scotland used GLP-1 class drugs for weight loss, including semaglutide drugs like 'Wegovy' and 'Ozempic', or tirzepatide drugs like 'Mounjaro'
Caloric restriction-induced life extension of rats and mice: a critique of proposed mechanisms
Less common but more concerning side effects include pancreatitis (rare but documented), gallbladder disease, and potential thyroid tumor risk based on animal studies, though human data has not confirmed the thyroid concern
Week 13 - 16: Initiate at 1.7 mg once weekly for 4 weeks
Both oral and injectable formats cause similar GLP-1related side effects including nausea, reduced appetite, and gastrointestinal changes
Studies in rats suggest that berberine increases GLP-1 secretion